Teva Pharmaceutical Industries has won the bidding contest for German generic drug maker Ratiopharm, beating out Pfizer and Actavis, three people close to the matter told Reuters.
One of the sources said Thursday that a contract had not yet been signed, the news service said.
This would make the deal the biggest generics takeover since Teva’s $7.5 billion purchase of U.S. rival Barr, and would give the winner a large slice of the world’s second-biggest generics market.
The auction is riveting drug makers and analysts because it has pitted the world’s biggest maker of brand-name drugs, the U.S. company Pfizer, against Teva, the global leader in generics.
Ratiopharm had global sales of 1.9 billion euros in 2008, nearly half of which were in Germany, according to the company’s Web site.
But Ratiopharm also sells its products in more than 30 other countries, including established markets like Spain and Canada and emerging economies like Russia. Over all, it is the world’s fifth-largest maker of generics, accounting for 3 percent of the global market, a report last year from BCC Research said.
Go to Article from Reuters »
Go to Article from Reuters via The New York Times »
Go to Related Item from DealBook »
Thursday, March 18, 2010
Teva to Take Over Ratiopharm, Report Says - DealBook Blog
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment